Acta Diabetologica

, Volume 56, Issue 10, pp 1103–1111 | Cite as

The impact of diabetes mellitus on clinical outcomes following chemotherapy for the patients with pancreatic cancer: a meta-analysis

  • Jichun Ma
  • Jing Wang
  • Long Ge
  • Bo Long
  • Junqiang ZhangEmail author
Review Article



A meta-analysis was performed to evaluate the prognostic impact of diabetes on the clinical outcome for patients with pancreatic cancer following the adjuvant chemotherapy.


To identify all researches and studies relevant to the prognostic impact of diabetes on the clinical outcome for patients with pancreatic cancer following the adjuvant chemotherapy, a comprehensive literature search was performed until January 30, 2018, by searching PubMed, EMBASE, and the Cochrane Library. The relevant data were extracted from included studies by two reviewers independently. HR and its 95% confidence interval (CI) were synthesized using STATA 12.0 software.


All of six studies consisting of 4241 pancreatic cancer patients (1034 patients with DM and 3207 patients without DM) were eligible and included in this meta-analysis. The result of meta-analysis under a fixed model showed that there are significant differences in overall survival (HR 1.16, 95% CI 1.08–1.25, P = 0.000) and T stage (OR 1.30, 95% CI 1.08–2.17, P = 0.005) between PC patients with DM following chemotherapy and PC patients without DM following chemotherapy. There was no significant difference in gender (OR 1.23, 95% CI 1.00–1.50, P = 0.051), tumor locations (OR 1.13, 95% CI 0.81–1.56, P = 0.476), cancer extent (OR 0.85, 95% CI 0.48–1.50, P = 0.569), N stage (OR 1.01, 95% CI 0.58–1.74, P = 0.973), and M stage (OR 0.64, 95% CI 0.21–1.99, P = 0.441) between diabetic PC patients and non-diabetic patients.


Diabetes mellitus patients who undergo chemotherapy for pancreatic cancer present with a reduced survival and lager tumor. Pancreatic cancer patients with DM also have a higher risk of death after chemotherapy.


Pancreatic cancer Diabetes mellitus Overall survival Meta-analysis 



This study was supported by the National Natural Science Foundation of China (Grant No. 81560480), Health Science Research Program of Gansu Province (No. GSWSKY2016-19), and Ph.D. Science Research Foundation of Lanzhou University Second Hospital.

Compliance with ethical standards

Conflict of interest

All authors declare that there was no any conflict of interests in this article.

Informed consent


Statement of human and animal rights

This study is a meta-analysis of other studies where all procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1975, as revised in 2008.


  1. 1.
    Siegel RL, Miller KD, Jemal A (2017) Cancer statistics, 2017. CA Cancer J Clinic 67(1):8–29CrossRefGoogle Scholar
  2. 2.
    Hidalgo M, Cascinu S, Kleeff J et al (2015) Addressing the challenges of pancreatic cancer: future directions for improving outcomes. Pancreatology 15(1):8–18CrossRefPubMedGoogle Scholar
  3. 3.
    Oettle H, Post S, Neuhaus P et al (2007) Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial. JAMA 297(3):267–277CrossRefPubMedGoogle Scholar
  4. 4.
    Everhart J, Wright D (1995) Diabetes mellitus as a risk factor for pancreatic cancer: a meta-analysis. JAMA 273(20):1605–1609CrossRefPubMedGoogle Scholar
  5. 5.
    Pannala R, Leirness JB, Bamlet WR et al (2008) Prevalence and clinical profile of pancreatic cancer-associated diabetes mellitus. Gastroenterology 134(4):981–987CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Li J, Cao G, Ma Q et al (2012) The bidirectional interation between pancreatic cancer and diabetes. World J Surg Oncol 10(1):171CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Hart PA, Chari ST (2013) Diabetes mellitus and pancreatic cancer: why the association matters? Pancreas 42(8):1207–1209CrossRefPubMedGoogle Scholar
  8. 8.
    Wang F, Gupta S, Holly EA (2006) Diabetes mellitus and pancreatic cancer in a population-based case–control study in the San Francisco Bay Area, California. Cancer Epidemiol Biomark Prev 14(15):1458–1463CrossRefGoogle Scholar
  9. 9.
    Amin S, Mhango G, Lin J et al (2016) Metformin improves survival in patients with pancreatic ductal adenocarcinoma and pre-existing diabetes: a propensity score analysis. Am J Gastroenterol 111(9):1350–1357CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Barone BB, Yeh HC, Snyder CF et al (2008) Long-term all-cause mortality in cancer patients with preexisting diabetes mellitus: a systematic review and meta-analysis. JAMA 300(23):2754–2764CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Chu CK, Mazo AE, Goodman M et al (2010) Preoperative diabetes mellitus and long-term survival after resection of pancreatic adenocarcinoma. Ann Surg Oncol 17(2):502–513CrossRefPubMedGoogle Scholar
  12. 12.
    Kleeff J, Costello E, Jackson R et al (2016) The impact of diabetes mellitus on survival following resection and adjuvant chemotherapy for pancreatic cancer. Br J Cancer 115(7):887–894CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Choi Y, Kim TY, Oh DY et al (2016) The impact of diabetes mellitus and metformin treatment on survival of patients with advanced pancreatic cancer undergoing chemotherapy. Cancer Res Treat 48(1):171CrossRefPubMedGoogle Scholar
  14. 14.
    Nakai Y, Isayama H, Sasaki T et al (2013) Clinical outcomes of chemotherapy for diabetic and nondiabetic patients with pancreatic cancer: better prognosis with statin use in diabetic patients. Pancreas 42(2):202–208CrossRefPubMedGoogle Scholar
  15. 15.
    He Xiang Y, Yao WY et al (2013) Resolution of new-onset diabetes after radical pancreatic resection; predicts long-term survival in patients with pancreatic ductal cell; adenocarcinoma. Ann Surg Oncol 20(12):3809–3816CrossRefPubMedGoogle Scholar
  16. 16.
    Zeiss K, Parhofer KG, Heinemann V et al (2013) Glucose and lipid metabolism in patients with advanced pancreatic cancer receiving palliative chemotherapy. Anticancer Res 33(1):287–292PubMedGoogle Scholar
  17. 17.
    Currie CJ, Poole CD, Jenkins-Jones S et al (2012) Mortality after incident cancer in people with and without type 2 diabetes: impact of metformin on survival. Diabetes Care 35(2):299–304CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    Del CM, Rangelova E, Segersvärd R et al (2016) Are there still indications for total pancreatectomy? Updates Surg 68(3):257–263CrossRefGoogle Scholar
  19. 19.
    Expert Committee on the Diagnosis and Classification of Diabetes Mellitus (2003) Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care 26(suppl 1):S5–S20Google Scholar
  20. 20.
    Hart PA et al (2016) Type 3c (pancreatogenic) diabetes mellitus secondary to chronic pancreatitis and pancreatic cancer. Lancet Gastroenterol Hepatol 1(3):226–237CrossRefPubMedPubMedCentralGoogle Scholar
  21. 21.
    Pannala R, Basu A, Petersen GM et al (2009) New-onset diabetes: a potential clue to the early diagnosis of pancreatic cancer. Lancet Oncol 10(1):88–95CrossRefPubMedPubMedCentralGoogle Scholar
  22. 22.
    Hackeng WM, Hruban RH, Offerhaus GJA et al (2016) Surgical and molecular pathology of pancreatic neoplasms. Diagn Pathol 11(1):47CrossRefPubMedPubMedCentralGoogle Scholar
  23. 23.
    Dong X, Li Y, Chang P et al (2011) Glucose metabolism gene variants modulate the risk of pancreatic cancer. Cancer Prev Res 4(5):758CrossRefGoogle Scholar
  24. 24.
    Garcea G, Dennison AR, Pattenden CJ et al (2015) Survival following curative resection for pancreatic ductal adenocarcinoma. A systematic review of the literature. JOP 9(2):99–132Google Scholar
  25. 25.
    Ilic M, Ilic I (2016) Epidemiology of pancreatic cancer. World J Gastroenterol 22(44):9694–9705CrossRefPubMedPubMedCentralGoogle Scholar
  26. 26.
    Lv X, Qiao W, Leng Y et al (2017) Impact of diabetes mellitus on clinical outcomes of pancreatic cancer after surgical resection: a systematic review and meta-analysis. PLoS ONE 12(2):e0171370CrossRefPubMedPubMedCentralGoogle Scholar
  27. 27.
    Tan J, You Y, Guo F et al (2017) Association of elevated risk of pancreatic cancer in diabetic patients: a systematic review and meta-analysis. Oncol Lett 13(3):1247–1255CrossRefPubMedPubMedCentralGoogle Scholar
  28. 28.
    Shen H, Zhan M, Wang W et al (2016) Impact of diabetes mellitus on the survival of pancreatic cancer: a meta-analysis. Oncotarg Ther 9(1):1679–1688Google Scholar
  29. 29.
    Becker AE, Hernandez YG, Frucht H et al (2014) Pancreatic ductal adenocarcinoma: risk factors, screening, and early detection. World J Gastroenterol 20(32):11182CrossRefPubMedPubMedCentralGoogle Scholar
  30. 30.
    Li D, Mao Y, Ping C et al (2014) Impacts of new-onset and long-term diabetes on clinical outcome of pancreatic cancer. Am J Cancer Res 5(10):3260–3269Google Scholar

Copyright information

© Springer-Verlag Italia S.r.l., part of Springer Nature 2019

Authors and Affiliations

  1. 1.Department of General SurgeryLanzhou University Second HospitalLanzhouPeople’s Republic of China
  2. 2.Department of EndocrinologyQilu Hospital of Shandong UniversityJinanPeople’s Republic of China
  3. 3.Evidence-Based Medicine CenterLanzhou UniversityLanzhouPeople’s Republic of China

Personalised recommendations